急性早幼粒细胞白血病的最新进展
Recent advances in acute promyelocytic leukaemia.
作者信息
Ng Chin-Hin, Chng Wee-Joo
机构信息
National University Cancer Institute, Singapore, Singapore.
出版信息
F1000Res. 2017 Jul 28;6:1273. doi: 10.12688/f1000research.10736.1. eCollection 2017.
Abstract
Acute promyelocytic leukaemia (APML) is a subtype of leukaemia arising from a distinct reciprocal translocation involving chromosomes 15 and 17, which results in the fusion gene. Over the past three decades, APML has been transformed from a highly fatal disease to a highly curable one. This drastic improvement is because of the introduction of a new treatment strategy with all-trans retinoic acid and, more recently, arsenic trioxide. The revolutionary treatment of APML has also paved the way for a new cancer treatment, which is genetically targeted therapy. In this review, we look into this amazing journey of transformation and provide recent advances in the management of APML.
摘要
急性早幼粒细胞白血病（APML）是白血病的一种亚型，由涉及15号和17号染色体的独特相互易位引起，这导致了融合基因的产生。在过去三十年中，APML已从一种高度致命的疾病转变为一种高度可治愈的疾病。这种巨大的改善得益于全反式维甲酸新治疗策略的引入，以及最近三氧化二砷的应用。APML的革命性治疗也为一种新的癌症治疗方法——基因靶向治疗铺平了道路。在这篇综述中，我们探究了这一惊人的转变历程，并介绍了APML治疗方面的最新进展。
相似文献
1
Recent advances in acute promyelocytic leukaemia.急性早幼粒细胞白血病的最新进展
F1000Res. 2017 Jul 28;6:1273. doi: 10.12688/f1000research.10736.1. eCollection 2017.
2
Acute promyelocytic leukaemia (APML) with cryptic PML-RARA fusion has a clinical course comparable to classical APML with t(15;17)(q24.1;q21.2) translocation.伴有隐匿性PML-RARA融合的急性早幼粒细胞白血病（APML）的临床病程与伴有t(15;17)(q24.1;q21.2)易位的经典APML相当。
Br J Haematol. 2019 Jul;186(1):155-157. doi: 10.1111/bjh.15738. Epub 2018 Dec 26.
3
How retinoic acid and arsenic transformed acute promyelocytic leukemia therapy.维甲酸和砷剂如何改变急性早幼粒细胞白血病的治疗。
J Mol Endocrinol. 2022 Oct 11;69(4):T69-T83. doi: 10.1530/JME-22-0141. Print 2022 Nov 1.
4
Acute promyelocytic leukaemia with a novel translocation t(16;17)(q12;p13): a case report.伴有新型易位t(16;17)(q12;p13)的急性早幼粒细胞白血病：一例报告
Malays J Pathol. 2016 Dec;38(3):311-313.
5
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.三氧化二砷和全反式维甲酸治疗所有风险组急性早幼粒细胞白血病（AML17）：一项随机、对照、3 期临床试验的结果。
Lancet Oncol. 2015 Oct;16(13):1295-305. doi: 10.1016/S1470-2045(15)00193-X. Epub 2015 Sep 14.
6
Pathogenesis, diagnosis and monitoring of residual disease in acute promyelocytic leukaemia.急性早幼粒细胞白血病残留病的发病机制、诊断及监测
Acta Haematol. 2004;112(1-2):55-67. doi: 10.1159/000077560.
7
Role of Prophylactic Steroids in Differentiation Syndrome.预防性类固醇在分化综合征中的作用。
Cureus. 2022 Sep 24;14(9):e29531. doi: 10.7759/cureus.29531. eCollection 2022 Sep.
8
Acute promyelocytic leukaemia with a PML-RARA insertional translocation and a chromosome 21 abnormality in XYY syndrome: case report.伴有PML-RARA插入性易位及XYY综合征中21号染色体异常的急性早幼粒细胞白血病：病例报告
J Int Med Res. 2014 Dec;42(6):1363-73. doi: 10.1177/0300060514540630. Epub 2014 Sep 15.
9
Chromosomal abnormality of acute promyelocytic leukemia other than -: a case report of acute promyelocytic leukemia with del(5q).除-之外的急性早幼粒细胞白血病染色体异常：一例伴有5号染色体长臂缺失的急性早幼粒细胞白血病病例报告
BMC Clin Pathol. 2016 Oct 4;16:16. doi: 10.1186/s12907-016-0038-4. eCollection 2016.
10
A complex translocation (1;17;15) with spliced short-type PML-RARA fusion transcripts in acute promyelocytic leukemia: A case report.急性早幼粒细胞白血病中伴有剪接短型PML-RARA融合转录本的复杂易位（1；17；15）：一例报告
Exp Ther Med. 2019 Feb;17(2):1360-1366. doi: 10.3892/etm.2018.7091. Epub 2018 Dec 13.
引用本文的文献
1
Coagulation Abnormalities and Risk Assessment in Acute Promyelocytic Leukemia: An Experience From a Resource-Constraint Country.急性早幼粒细胞白血病的凝血异常与风险评估：来自资源受限国家的经验
Cureus. 2022 Jun 17;14(6):e26026. doi: 10.7759/cureus.26026. eCollection 2022 Jun.
2
Transcriptomic profiling of blood from autoimmune hepatitis patients reveals potential mechanisms with implications for management.自身免疫性肝炎患者血液的转录组谱分析揭示了潜在的机制，这些机制对治疗有影响。
PLoS One. 2022 Mar 21;17(3):e0264307. doi: 10.1371/journal.pone.0264307. eCollection 2022.
3
G/M cell cycle arrest and apoptosis induced by COH-203 in human promyelocytic leukemia HL-60 cells.COH - 203诱导人早幼粒细胞白血病HL - 60细胞发生G/M期细胞周期阻滞和细胞凋亡。
Oncol Lett. 2021 Dec;22(6):815. doi: 10.3892/ol.2021.13076. Epub 2021 Sep 28.
4
AXL receptor tyrosine kinase: a possible therapeutic target in acute promyelocytic leukemia.AXL 受体酪氨酸激酶：急性早幼粒细胞白血病的可能治疗靶点。
BMC Cancer. 2021 Jun 17;21(1):713. doi: 10.1186/s12885-021-08450-y.
5
Ubiquitin and SUMO conjugation as biomarkers of acute myeloid leukemias response to chemotherapies.泛素和 SUMO 缀合作为急性髓系白血病对化疗反应的生物标志物。
Life Sci Alliance. 2020 Apr 17;3(6). doi: 10.26508/lsa.201900577. Print 2020 Jun.
6
Overall survival of adult acute myeloid leukemia based on cytogenetic and molecular abnormalities during 5 years in a single center study.一项单中心研究中基于细胞遗传学和分子异常的成人急性髓系白血病5年总生存率
Saudi Med J. 2019 Nov;40(11):1171-1176. doi: 10.15537/smj.2019.11.24584.
7
The SUMO Pathway in Hematomalignancies and Their Response to Therapies.SUMO 通路在血液系统恶性肿瘤及其对治疗的反应中的作用。
Int J Mol Sci. 2019 Aug 9;20(16):3895. doi: 10.3390/ijms20163895.
本文引用的文献
1
First experience of the AML-Berlin-Frankfurt-Münster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and all-trans retinoid acid.急性早幼粒细胞白血病柏林-法兰克福-明斯特协作组对标准风险小儿急性早幼粒细胞白血病患者使用三氧化二砷和全反式维甲酸治疗的首次经验。
Pediatr Blood Cancer. 2017 Aug;64(8). doi: 10.1002/pbc.26461. Epub 2017 Jan 23.
2
Long-term outcome of acute promyelocytic leukemia treated with all--retinoic acid, arsenic trioxide, and gemtuzumab.全反式维甲酸、三氧化二砷和吉妥单抗治疗急性早幼粒细胞白血病的长期疗效
Blood. 2017 Mar 9;129(10):1275-1283. doi: 10.1182/blood-2016-09-736686. Epub 2016 Dec 21.
3
Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia.初发及复发急性早幼粒细胞白血病的全面突变分析
Leukemia. 2016 Dec;30(12):2430. doi: 10.1038/leu.2016.237. Epub 2016 Oct 7.
4
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.维甲酸和三氧化二砷与维甲酸和化疗治疗非高危急性早幼粒细胞白血病的疗效比较：意大利-德国 APL0406 随机试验的最终结果。
J Clin Oncol. 2017 Feb 20;35(6):605-612. doi: 10.1200/JCO.2016.67.1982. Epub 2016 Oct 31.
5
PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy.初诊急性早幼粒细胞白血病采用 ATRA 和 ATO 或 ATRA 和化疗治疗时的 PML-RARα 动力学和 FLT3-ITD 突变的影响。
Leukemia. 2016 Oct;30(10):1987-1992. doi: 10.1038/leu.2016.122. Epub 2016 May 2.
6
Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients.急性早幼粒细胞白血病的预后因素：定义高危患者的策略
Ann Hematol. 2016 Apr;95(5):673-80. doi: 10.1007/s00277-016-2622-1. Epub 2016 Feb 26.
7
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.三氧化二砷和全反式维甲酸治疗所有风险组急性早幼粒细胞白血病（AML17）：一项随机、对照、3 期临床试验的结果。
Lancet Oncol. 2015 Oct;16(13):1295-305. doi: 10.1016/S1470-2045(15)00193-X. Epub 2015 Sep 14.
8
Successful treatment of acute promyelocytic leukemia with a t(X;17)(p11.4;q21) and BCOR-RARA fusion gene.采用t(X;17)(p11.4;q21)和BCOR-RARA融合基因成功治疗急性早幼粒细胞白血病。
Cancer Genet. 2015 Apr;208(4):162-3. doi: 10.1016/j.cancergen.2015.01.008. Epub 2015 Feb 2.
9
Oral arsenic and retinoic acid for non-high-risk acute promyelocytic leukemia.口服砷剂和维甲酸治疗非高危急性早幼粒细胞白血病。
N Engl J Med. 2014 Dec 4;371(23):2239-41. doi: 10.1056/NEJMc1412035.
10
Tamibarotene as maintenance therapy for acute promyelocytic leukemia: results from a randomized controlled trial.他扎罗汀作为急性早幼粒细胞白血病维持治疗的疗效：一项随机对照试验的结果。
J Clin Oncol. 2014 Nov 20;32(33):3729-35. doi: 10.1200/JCO.2013.53.3570. Epub 2014 Sep 22.
Zotero 插件